

April 19, 2024

SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director,  
President and Chief Executive Officer  
Takaaki Fukushima  
Executive Vice President, Corporate Officer and Chief Financial Officer  
TEL: +81-3-5472-1125

**Notice of Completion of Payment for the New Share Issue through  
Third-Party Allotment (5th Allotment) based on the Agreement to Set up  
a STRaight-Equity Issue Program (“STEP”)**

SymBio Pharmaceuticals Limited (the “Company”), as announced in the “Notice of Agreement to Set up a STRaight-Equity Issue Program (“STEP”) and Issue New Shares through Third-Party Allotment” dated October 6, 2023, resolved at a Board of Directors’ meeting held on the same day of the release to enter into an agreement with EVO FUND (the “Allottee”) to set up an equity issue program (the “Agreement to Set up an Equity Issue Program”), and based on the equity issue program established under the Agreement to Set up an Equity Issue Program (the “Program”), to issue new shares in five tranches (shares issued to the Allottee, whether individually or collectively, under the Program are referred to as the “Shares”). The Company hereby announces that the payment procedures for the 5th allotment of the Shares has been completed, as below.

1. Outline of Shares to Be Issued

(1) Class and number of shares to be issued	1,050,000 common shares of the Company
(2) Issue price and total value of shares to be issued	¥187 per share, for a total of ¥196,350,000
(3) Increase in capital stock	¥93.5 per share, for a total of ¥98,175,000
(4) Increase in legal capital surplus	¥93.5 per share, for a total of ¥98,175,000
(5) Deadline for application	April 19, 2024
(6) Due date of payment	April 19, 2024
(7) Allotment method:	Third-party allotment
(8) Allottee	EVO FUND

2. Change in the Total Number of Shares Issued and Capital Stock Due to the Issue of the Shares

Total number of shares issued prior to the capital increase	44,845,981 shares (capital stock prior to the capital increase: ¥18,225,841,683)
Increase in the number of shares issued due to the capital increase	1,050,000 shares (increase in capital stock: ¥98,175,000)
Total number of shares issued after the capital increase	45,895,981 shares (capital stock after the capital increase: ¥18,324,016,683)

Note: This document does not constitute an investment solicitation for any securities for sale. This document has been prepared to publicly announce matters related to the issuance of the common stock, and not for the purpose of soliciting investment. This document does not constitute an offer of investment in nor solicitation for purchase of the common stock within the United States. Regarding the common stock, SymBio has not registered, and is not scheduled to register, any of them under the United States Securities Act of 1933. The securities may not be offered or sold in the United States without a registration or an exemption from registration under the United States Securities Act of 1933. No offer of securities in the United States will be made in connection with this transaction.